Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 26;11(3):101.
doi: 10.3390/pharmaceutics11030101.

Neuronanomedicine: An Up-to-Date Overview

Daniel Mihai Teleanu  1 , Cristina Chircov  2   3 , Alexandru Mihai Grumezescu  4   5 , Raluca Ioana Teleanu  6
Affiliations
Review

Neuronanomedicine: An Up-to-Date Overview

Daniel Mihai Teleanu et al. Pharmaceutics. .

Abstract

The field of neuronanomedicine has recently emerged as the bridge between neurological sciences and nanotechnology. The possibilities of this novel perspective are promising for the diagnosis and treatment strategies of severe central nervous system disorders. Therefore, the development of nano-vehicles capable of permeating the blood⁻brain barrier (BBB) and reaching the brain parenchyma may lead to breakthrough therapies that could improve life expectancy and quality of the patients diagnosed with brain disorders. The aim of this review is to summarize the recently developed organic, inorganic, and biological nanocarriers that could be used for the delivery of imaging and therapeutic agents to the brain, as well as the latest studies on the use of nanomaterials in brain cancer, neurodegenerative diseases, and stroke. Additionally, the main challenges and limitations associated with the use of these nanocarriers are briefly presented.

Keywords: central nervous system disorders; delivery of imaging and therapeutic agents; inorganic nanocarriers; nano-vehicles; nanotechnology; neurological sciences; neuronanomedicine; organic nanocarriers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
A summary of the various types of nanocarriers for brain targeting.
Figure 2
Figure 2
The main pathways of crossing the BBB for each type of the described nanocarriers.
Figure 3
Figure 3
The applications of nanomaterials as nanocarriers in brain cancer, neurodegenerative diseases, and stroke therapy.
See this image and copyright information in PMC

References

    1. Kennedy M.B. Biochemistry and neuroscience: The twain need to meet. Curr. Opin. Neurobiol. 2017;43:79–86. doi: 10.1016/j.conb.2017.01.004. - DOI - PMC - PubMed
    1. Rivnay J., Wang H., Fenno L., Deisseroth K., Malliaras G.G. Next-generation probes, particles, and proteins for neural interfacing. Sci. Adv. 2017;3:e1601649. doi: 10.1126/sciadv.1601649. - DOI - PMC - PubMed
    1. Mader B.J., Boulis N.M. Chapter 9—Viral Vectors and Other Modulatory Biologics. In: Arle J., Shils J., editors. Innovative Neuromodulation. Academic Press; San Diego, CA, USA: 2017. pp. 171–205.
    1. Crean P.M., Tirupathi S. 24-Essentials of Neurology and Neuromuscular Disorders. In: Coté C.J., Lerman J., Anderson B.J., editors. A Practice of Anesthesia for Infants and Children. 6th ed. Elsevier; Philadelphia, PA, USA: 2019. pp. 561.e4–580.e4.
    1. Barnabas W. Drug targeting strategies into the brain for treating neurological diseases. J. Neurosci. Methods. 2018;311:133–146. doi: 10.1016/j.jneumeth.2018.10.015. - DOI - PubMed

LinkOut - more resources